Kyle Bass Group Gets PTAB To Review 2 Celgene Patents

Law360, New York (October 27, 2015, 8:38 PM EDT) -- The Patent Trial and Appeal Board on Tuesday agreed to review two more drug patents challenged by hedge fund manager Kyle Bass, finding that his organization has shown that two Celgene Corp. patents related to the cancer drugs Thalomid, Revlimid and Pomalyst are likely invalid.

The three drugs are either contain thalidomide, which was largely taken off the market in 1962 because it can cause severe birth defects, or are similar to it. The patents that Bass challenged cover a computerized method of distributing the drugs...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.